Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Insomnia Market

ID: MRFR/Pharma/0102-HCR
85 Pages
Rahul Gotadki
Last Updated: April 22, 2026

Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of diseases (poor quality of sleep, sleep maintenance and other) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Insomnia Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type of Therapy (USD Billion) | |
      1. 4.1.1 Pharmacological Therapy | |
      2. 4.1.2 Non-Pharmacological Therapy |
    2. 4.2 Healthcare, BY Drug Formulation (USD Billion) | |
      1. 4.2.1 Capsules | |
      2. 4.2.2 Tablets | |
      3. 4.2.3 Others |
    3. 4.3 Healthcare, BY Type of Disease Condition (USD Billion) | |
      1. 4.3.1 Poor Quality of Sleep | |
      2. 4.3.2 Sleep Maintenance | |
      3. 4.3.3 Others |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Pfizer Inc (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Merck & Co Inc (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Eli Lilly and Company (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Sanofi (FR) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AstraZeneca (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Teva Pharmaceutical Industries Ltd (IL) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Bristol-Myers Squibb Company (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Johnson & Johnson (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Novartis AG (CH) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE OF THERAPY |
    7. 6.4 US MARKET ANALYSIS BY DRUG FORMULATION |
    8. 6.5 US MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    9. 6.6 CANADA MARKET ANALYSIS BY TYPE OF THERAPY |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG FORMULATION |
    11. 6.8 CANADA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY TYPE OF THERAPY |
    14. 6.11 GERMANY MARKET ANALYSIS BY DRUG FORMULATION |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    16. 6.13 UK MARKET ANALYSIS BY TYPE OF THERAPY |
    17. 6.14 UK MARKET ANALYSIS BY DRUG FORMULATION |
    18. 6.15 UK MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    19. 6.16 FRANCE MARKET ANALYSIS BY TYPE OF THERAPY |
    20. 6.17 FRANCE MARKET ANALYSIS BY DRUG FORMULATION |
    21. 6.18 FRANCE MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    22. 6.19 RUSSIA MARKET ANALYSIS BY TYPE OF THERAPY |
    23. 6.20 RUSSIA MARKET ANALYSIS BY DRUG FORMULATION |
    24. 6.21 RUSSIA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    25. 6.22 ITALY MARKET ANALYSIS BY TYPE OF THERAPY |
    26. 6.23 ITALY MARKET ANALYSIS BY DRUG FORMULATION |
    27. 6.24 ITALY MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    28. 6.25 SPAIN MARKET ANALYSIS BY TYPE OF THERAPY |
    29. 6.26 SPAIN MARKET ANALYSIS BY DRUG FORMULATION |
    30. 6.27 SPAIN MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE OF THERAPY |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY DRUG FORMULATION |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY TYPE OF THERAPY |
    36. 6.33 CHINA MARKET ANALYSIS BY DRUG FORMULATION |
    37. 6.34 CHINA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    38. 6.35 INDIA MARKET ANALYSIS BY TYPE OF THERAPY |
    39. 6.36 INDIA MARKET ANALYSIS BY DRUG FORMULATION |
    40. 6.37 INDIA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    41. 6.38 JAPAN MARKET ANALYSIS BY TYPE OF THERAPY |
    42. 6.39 JAPAN MARKET ANALYSIS BY DRUG FORMULATION |
    43. 6.40 JAPAN MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE OF THERAPY |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY DRUG FORMULATION |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE OF THERAPY |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY DRUG FORMULATION |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    50. 6.47 THAILAND MARKET ANALYSIS BY TYPE OF THERAPY |
    51. 6.48 THAILAND MARKET ANALYSIS BY DRUG FORMULATION |
    52. 6.49 THAILAND MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    53. 6.50 INDONESIA MARKET ANALYSIS BY TYPE OF THERAPY |
    54. 6.51 INDONESIA MARKET ANALYSIS BY DRUG FORMULATION |
    55. 6.52 INDONESIA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE OF THERAPY |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY DRUG FORMULATION |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY TYPE OF THERAPY |
    61. 6.58 BRAZIL MARKET ANALYSIS BY DRUG FORMULATION |
    62. 6.59 BRAZIL MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    63. 6.60 MEXICO MARKET ANALYSIS BY TYPE OF THERAPY |
    64. 6.61 MEXICO MARKET ANALYSIS BY DRUG FORMULATION |
    65. 6.62 MEXICO MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE OF THERAPY |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY DRUG FORMULATION |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF THERAPY |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG FORMULATION |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF THERAPY |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY DRUG FORMULATION |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF THERAPY |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY DRUG FORMULATION |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE OF THERAPY |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY DRUG FORMULATION |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY TYPE OF DISEASE CONDITION |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY TYPE OF THERAPY, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY TYPE OF THERAPY, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY DRUG FORMULATION, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY DRUG FORMULATION, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY TYPE OF DISEASE CONDITION, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY TYPE OF DISEASE CONDITION, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DRUG FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY TYPE OF DISEASE CONDITION, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type of Therapy (USD Billion, 2025-2035)

  • Pharmacological Therapy
  • Non-Pharmacological Therapy

Healthcare By Drug Formulation (USD Billion, 2025-2035)

  • Capsules
  • Tablets
  • Others

Healthcare By Type of Disease Condition (USD Billion, 2025-2035)

  • Poor Quality of Sleep
  • Sleep Maintenance
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions